{"id":"NCT01154036","sponsor":"Organon and Co","briefTitle":"MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)","officialTitle":"A Randomized, Double-Blind, Active-Controlled, Multicenter Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk Who Are Not Adequately Controlled With Atorvastatin 10 mg: A Comparison of the Efficacy and Safety of Switching to Coadministration Ezetimibe and Atorvastatin Versus Doubling the Dose of Atorvastatin or Switching to Rosuvastatin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-07","primaryCompletion":"2012-09","completion":"2012-10","firstPosted":"2010-06-30","resultsPosted":"2014-02-12","lastUpdate":"2022-02-09"},"enrollment":1547,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"ezetimibe 10 mg","otherNames":[]},{"type":"DRUG","name":"atorvastatin","otherNames":[]},{"type":"DRUG","name":"Comparator: rosuvastatin","otherNames":[]}],"arms":[{"label":"Phase I: ezetimibe (EZ) 10 mg + atorvastatin (Atorva) 10 mg","type":"EXPERIMENTAL"},{"label":"Phase I: Atorvastatin 20 mg","type":"ACTIVE_COMPARATOR"},{"label":"Phase I: Rosuvastatin 10 mg","type":"ACTIVE_COMPARATOR"},{"label":"Phase II: EZ 10mg+Atorva 10mg","type":"EXPERIMENTAL"},{"label":"Phase II: EZ 10mg + Atorva 20mg [A]","type":"EXPERIMENTAL"},{"label":"Phase II: Atorva 40mg","type":"ACTIVE_COMPARATOR"},{"label":"Phase II: EZ 10mg + Atorva 20mg [R]","type":"EXPERIMENTAL"},{"label":"Phase II: Rosuvastatin 20mg","type":"ACTIVE_COMPARATOR"}],"summary":"This study will compare the lipid-altering efficacy and safety of switching to co-administration of ezetimibe and atorvastatin versus treatment with atorvastatin or rosuvastatin in high cardiovascular risk patients with hypercholesterolemia who have not achieved specified low-density lipoprotein cholesterol (LDL-C) levels. The primary hypothesis is that the co-administration of ezetimibe 10 mg and atorvastatin 10 mg will be superior to both atorvastatin 20 mg and rosuvastatin 10 mg with respect to the percentage reduction in low-density lipoprotein-cholesterol (LDL-C) after 6 weeks of treatment.","primaryOutcome":{"measure":"Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)","timeFrame":"Baseline and Week 6 (end of Phase I )","effectByArm":[{"arm":"Phase I: Ezetimibe (EZ) 10 mg + Atorvastatin (Atorva) 10 mg","deltaMin":-24.8,"sd":23.6},{"arm":"Phase I: Atorvastatin 20 mg","deltaMin":-10.1,"sd":20.8},{"arm":"Phase I: Rosuvastatin 10 mg","deltaMin":-13.8,"sd":22.8}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":14},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25985907","24063830"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":120},"commonTop":[]}}